-
[Industry News] The first KRAS inhibitor was approved for the market, and it may become history!
Time of Update: 2021-06-11
Click on the translational medicine website above to subscribe to our dry goods | Reliable | Practical May 28, 2021, FDA announced accelerated approval of KRAS inhibitor Lumakras (active ingredient sotorasib, AMG510) for the treatment of non-small cell lung cancer with KRAS-G12C mutation (NSCLC) patients, this is the first anti-cancer therapy targeting specific KRAS gene mutations.
-
2021 ASCO prospective initial treatment of multiple myeloma consolidation treatment plan exploration
Time of Update: 2021-06-11
Abstract 8000: A comparative study on the efficacy of carfilzomib, cyclophosphamide, dexamethasone consolidation therapy and autologous hematopoietic stem cell transplantation in newly diagnosed MM patients Background NDMM patients usually get higher minimal residual after induction therapy and consolidation therapy The negative rate of MRD, whether these patients need autologous hematopoietic stem cell transplantation (ASCT) remains to be evaluated.
-
The U.S. FDA grants Janssen the BCMA/CD dual anti-breakthrough therapy designation medical Maimeng broke
Time of Update: 2021-06-11
MedClub New Observation June 3, 2021/MedClub News/--Recently, Janssen, a subsidiary of Johnson & Johnson, announced that the FDA has granted its bispecific antibody teclistamab breakthrough therapy designation.
-
Geng Hao, Anhui Medical University, et al.: Exosomes and bladder cancer: new biomarkers and targets
Time of Update: 2021-06-11
JZUS-B welcomes outstanding scholars at home and abroad to contribute the latest scientific research results, controversial topics, review papers, and organize the publication of hot albums.
-
Professor Niu Ting: Progress in the diagnosis and treatment of diffuse large B-cell lymphoma
Time of Update: 2021-06-11
At this meeting, Professor Niu Ting from West China Hospital of Sichuan University gave a theme report on "Diffuse Large B-Cell Lymphoma (DLBCL) Diagnosis and Treatment Progress".
-
Harvard 160,000 people study: Diabetes is associated with a nearly 40% increase in cancer risk, especially liver cancer
Time of Update: 2021-06-11
Image source: After 123RF adjusted for other factors, researchers found that type 2 diabetes was associated with a higher risk of cancer.
Compared with subjects without type 2 diabetes, having type 2 diabetes is associated with a 21% increase in overall cancer risk.
-
Zhaxin: Single people are more susceptible to cancer, and the death rate after cancer is higher
Time of Update: 2021-06-11
The study shows that middle-aged men’s loneliness is associated with an increased risk of cancer, and that single men (unmarried, widowed, divorced) have a higher mortality rate for cancer patients.
-
2021 EHA prospective CD22-CAR-T cell therapy to treat adult R/R B-ALL
Time of Update: 2021-06-11
Although the current CD19-CAR-T cell therapy for relapsed or refractory acute B-lymphocytic leukemia (R/R B-ALL) has achieved a high complete remission (CR) rate, there are still some patients in CD19-CAR -The recurrence of T cell therapy and the detection of CD22 expression have become an urgent problem to be solved.
-
JAMA Netw Open: The best initial treatment for advanced oropharyngeal squamous cell carcinoma?
Time of Update: 2021-06-10
This study aims to compare the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment for advanced oropharyngeal squamous cell carcinoma.
All in all, in this study, the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment in advanced oropharyngeal squamous cell carcinoma is still the same.
-
ASCO 2021: Overview of Oral Abstracts for Metastatic Breast Cancer Special Session
Time of Update: 2021-06-10
1000The Phase III MONALEESA-3 trial (NCT02422615) has demonstrated that in postmenopausal patients with HR+/HER2-ABC, RIB (a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)) plus FUL and placebo Compared with (PBO) plus FUL as first-line (1L) or second-line (2L) treatment, OS has a significant improvement (median, less than VS.
-
ASCO 2021: New progress in skin cancer immunotherapy (continuous update)
Time of Update: 2021-06-10
Nivolumab alone in the treatment of advanced melanoma (Abstract 9503)The RELATIVITY-047 study showed that the treatment of anti-PD-1 therapy nivolumab plus LAG-3 blocking antibody relatlimab prolonged the time of disease progression in patients with previously untreated, unresectable or metastatic melanoma.
-
JNCI: The depression of young breast cancer survivors should not be underestimated!
Time of Update: 2021-06-10
Screening PHQ-9 is a validated, widely used, short questionnaire, mainly used to assess depression symptoms and identify individuals at risk of depression.
diagnosisScreening for depressive symptoms is especially important for high-risk groups, including young breast cancer survivors (YBCS).
-
ASCO 2021: Summary Overview and Outlook 3 Roche atezolizumab is expected to be the first immunotherapy approved for perioperative treatment of non-small cell lung cancer
Time of Update: 2021-06-10
Roche Art Zhu monoclonal antibody (Tecentriq) is expected to become the first to be approved for perioperative treatment of non-small cell lung cancer immunity data Impower-010 in the study therapy, the study was just released Virtual Asco meeting on aid research Derived from.
-
ASCO 2021 opens, the fairness of cancer treatment in the context of the pandemic attracts attention
Time of Update: 2021-06-10
Throughout her career, Pierce has been committed to solving fairness issues in healthcare, especially cancer care; the pandemic has highlighted the gap in access to care and results, and from the beginning, oncologists have been prepared Good to meet a wave of late diagnosis , because patients missed screening and follow-up care, or because of the pandemic public health measures have to change the treatment plan.
-
JCO: Residual after neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC), the efficacy and safety of platinum-based chemotherapy versus capecitabine: a randomized phase III study (ECOG-ACRIN EA1131)
Time of Update: 2021-06-10
Compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC).
Compared with capecitabine adjuvant chemotherapy, platinum-based adjuvant chemotherapy cannot improve the prognosis of patients with residual basal TNBC after neoadjuvant chemotherapy (NAC).
-
Cancer Sci: Aletinib can effectively and safely treat relapsed or refractory ALK-positive lymphoma
Time of Update: 2021-06-10
An open-label phase II trial aims to study the efficacy and safety of the second-generation ALK inhibitor aletinib in patients with relapsed or refractory ALK-positive asexual large cell lymphoma (ALCL).
-
Gastric cancer patients over 55 years old account for 70% of the total number of patients. How to stay away from cancer?
Time of Update: 2021-06-10
Among them, the number of new cases of breast cancer reached 2.
In China, the number of new cancer cases reached 4.
57 million, and the number of cancer deaths reached 3 million, ranking first in the world.
-
Takeda reported the latest results of mobocertinib, further confirming the clinical benefits of patients with EGFR exon 20 insertion + mNSCLC
Time of Update: 2021-06-10
( TSE:4502/NYSE:TAK ) ("Takeda") today released mobocertinib (TAK-788) for oral treatment of epidermal growth factor receptor (EGFR) Exon 20 insertion mutation positive (insert+) metastatic non-small cell lung cancer (m NSCLC ) Phase 1/2 clinical trial data.
-
Merck's oncology product lineup data presented on ASCO21 highlights major advances in cancer treatment
Time of Update: 2021-06-10
BAVENCIO 's approved indications In the United States, BAVENCIO is suitable for the maintenance treatment of locally advanced or metastatic urothelial carcinoma (UC) patients who have not progressed after first-line platinum-containing chemotherapy .
-
JNCCN: The risk of tumor-specific death in patients with neuroendocrine tumors (NETs)
Time of Update: 2021-06-10
The 5-year risk of tumor-specific death in the overall population of NETs is higher than that of non-tumor-related deaths, with mortality rates of 7.
The 5-year risk of tumor-specific death in the overall population of NETs is higher than that of non-tumor-related deaths, with mortality rates of 7.
